SCHEMBL4914403

SCHEMBL4914403

O=C(COc1ccc(Cl)cc1)Nc1ccccc1-c1nnn[nH]1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.56
RAB9A P51151 6/20 0.56
MAPT P10636 3/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
LMNA P02545 1/20 0.55
HPGD P15428 1/20 0.55
NPSR1 Q6W5P4 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
POLB P06746 3/20 0.48
TSHR P16473 2/20 0.48
TP53 P04637 1/20 0.48
ALDH1A1 P00352 1/20 0.47
SENP2 Q9HC62 1/20 0.47
SENP1 Q9P0U3 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5061520 0.89 NPC1 (0.58) NPC1RAB9AMAPTL3MBTL1LMNA
SCHEMBL1307131 0.89 NPC1 (0.48) NPC1RAB9AMAPTL3MBTL1LMNA
SCHEMBL1308139 0.87 RAB9A (0.58) NPC1RAB9AL3MBTL1LMNACYP1A2
SCHEMBL1309974 0.82 NOTUM (0.49) NPC1RAB9AMAPTL3MBTL1LMNA
SCHEMBL1309972 0.79 L3MBTL1 (0.59) NPC1RAB9AMAPTL3MBTL1LMNA
SCHEMBL2635578 0.77 POLB (0.43) NPC1RAB9AMAPTL3MBTL1LMNA
SCHEMBL6712023 0.77 RAB9A (0.46) NPC1RAB9AMAPTL3MBTL1LMNA
SCHEMBL1308511 0.77 THRB (0.47) NPC1RAB9AL3MBTL1LMNAHPGD
SCHEMBL6707929 0.76 GAA (0.45) NPC1RAB9AMAPTL3MBTL1LMNA
SCHEMBL1310212 0.75 ALDH1A1 (0.56) LMNAHPGDSMN1; SMN2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US claimed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US claimed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US claimed
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US disclosed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US disclosed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus HCCS, ALAD, HAVCR2 NPC1 1608/4885RAB9A 2260/4885MAPT 4708/4885
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS HCCS, ALAD, HAVCR2 NPC1 1608/4885RAB9A 2260/4885MAPT 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.